Overview

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

Status:
Completed
Trial end date:
2020-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of IGIV 10% in patients with autoimmune encephalitis
Phase:
Phase 2
Details
Lead Sponsor:
Green Cross Corporation
Treatments:
Antibodies
Immunoglobulin G
Immunoglobulins
Immunoglobulins, Intravenous